LEADER 03507nam  22005175  450 
001 9910300440103321
005 20200630010125.0
010   $a3-319-93339-6
024 7 $a10.1007/978-3-319-93339-9
035   $a(CKB)4100000006098221
035   $a(MiAaPQ)EBC5504865
035   $a(DE-He213)978-3-319-93339-9
035   $a(iGPub)SPNA0057691
035   $a(PPN)229916597
035   $a(EXLCZ)994100000006098221
100   $a20180831d2018      u|             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aGenitourinary Cancers $b[electronic resource] /$fedited by Siamak Daneshmand, Kevin G. Chan
205   $a1st ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (308 pages) $cillustrations
225 1 $aCancer Treatment and Research,$x0927-3042 ;$v175
311   $a3-319-93338-8 
320   $aIncludes bibliographical references.
327   $aNew Imaging Techniques in Prostate Cancer -- Targeted ablative therapies for prostate cancer -- Prostate cancer markers -- Prognostic value of CTC?s in urologic cancers -- Management of Small Renal Masses -- Advances in the Treatment of Metastatic Renal Cell Carcinoma.-Imaging in urologic cancers  -- Molecular prognostication in Bladder cancer -- Early cystectomy for high risk non-muscle invasive disease -- Care-coordination pathway after radical cystectomy -- Current role of checkpoint inhibitors in urologic cancers -- ) The Cancer Genome Atlas Project -- Prognostic models in germ cell tumors -- Modern management of testicular cancer.
330   $aThis book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.
410  0$aCancer Treatment and Research,$x0927-3042 ;$v175
606   $aOncology  
606   $aUrology
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aUrology$3https://scigraph.springernature.com/ontologies/product-market-codes/H62002
615  0$aOncology  .
615  0$aUrology.
615 14$aOncology.
615 24$aUrology.
676   $a616.9946
702   $aDaneshmand$b Siamak$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aChan$b Kevin G$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300440103321
996   $aGenitourinary Cancers$91751148
997   $aUNINA